

Supplementary Table 1. Results from survival analyses by adjuvant therapies in patients with no residual disease after surgery

Variable	PFS				DSS			
	Patients, n	Events, n	5-yr % (\pm SE)	p	Patients, n	Events, n	5-yr % (\pm SE)	p
All patients				0.394				0.51
Observation	43	5	89.7 (4.9)		40	2	92.6 (5.1)	
RT	15	4	77.4 (11.5)		15	1	92.3 (7.4)	
Medical therapy*	16	4	71.4 (12.2)		15	2	79.5 (13.1)	
RT and medical therapy	8	3	85.7 (13.2)		7	0	100	
Stage I				<0.001				0.86
Observation	35	3	93.3 (4.6)		32	2	90.4 (6.5)	
RT	10	2	77.8 (13.9)		10	1	88.9 (10.5)	
Medical therapy	7	0	100		6	0	100	
RT and medical therapy	2	1	NR		2	0	NR	
Stage I				0.50				0.85
Observation	35	3	93.3 (4.6)		32	2	90.4 (6.5)	
Adjuvant therapy (any)	19	3	82.8 (9.1)		18	1	93.8 (6.1)	
Stage II-IV				0.31				0.09
Observation	8	2	75.0 (15.3)		8	0	100	
RT	5	2	75.0 (21.7)		5	0	100	
Medical therapy	9	4	44.0 (18.9)		9	2	55.6 (24.8)	
RT and medical therapy	6	2	100		5	0	100	
Stage II-IV				0.81				0.32
Observation	8	2	75.0 (15.3)		8	0	100	
Adjuvant therapy (any)	20	8	69.5 (11.5)		19	2	84.4 (10.2)	

PFS, progression-free survival; DSS, disease-free survival; SE, standard error; RT, radiation therapy; NR, not reached; NA, not available

*all medical therapy was hormonal – progestin, gonadotropin-releasing hormone, or aromatase inhibitor